WeightWatchers has emerged from bankruptcy following a major debt restructuring aimed at improving its competitive position against popular weight loss medications such as Ozempic and Mounjaro, which it has characterized as "quick fix" solutions. The company’s chief executive has committed to a new strategic direction, including a focus on addressing menopause-related weight challenges. To support this pivot, WeightWatchers recently appointed Dr. Kim Boyd as its new medical chief. Meanwhile, recent studies highlight that GLP-1 receptor agonist medications like Ozempic, originally developed for type 2 diabetes, have shown efficacy not only in weight loss but also in normalizing testosterone levels in men with obesity or type 2 diabetes. However, medical experts caution against the irresponsible use of these drugs despite their growing popularity and impact on obesity treatment.